FrancophonIA/ELRC3.0 huggingface dataset:
English: Oncaspar also comes with the advantage of requiring fewer injections as the medicine stays longer in the body than some other asparaginases.
Estonian: Oncaspari eelis on väiksem arv süste, sest ravim püsib organismis kauem kui mõni muu asparaginaasravim.
English: What are the risks associated with Oncaspar?
Estonian: Mis riskid Oncaspariga kaasnevad?
English: The cancer cells need this amino acid to grow and multiply, and so its reduction in the blood causes the cells to die.
Estonian: Vähirakud vajavad seda aminohapet kasvamiseks ja paljunemiseks, seega põhjustab selle väiksem sisaldus veres nende rakkude hävimise.
English: The asparaginase enzyme in this medicine is linked to a chemical which slows down its removal from the body and can reduce the risk of allergic reactions.
Estonian: Ravimis sisalduv ensüüm asparaginaas on seotud keemilise ainega, mis pikendab selle püsimist organismis ja vähendab allergiareaktsioonide riski.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Oncaspar have been included in the summary of product characteristics and the package leaflet.
Estonian: Oncaspari ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Studies showed Oncaspar to be effective in patients with ALL, including patients who were allergic to asparaginase.
Estonian: Uuringud tõendasid, et Oncaspar on efektiivne ägeda lümfoblastleukeemiaga patsientidel, sealhulgas nendel, kes on allergilised asparaginaasi suhtes.
English: In another study of 76 children whose cancer returned after earlier treatment, around 40% of Oncaspar-treated patients (some of whom were allergic to other asparaginase treatments) were cleared of the cancer, compared with 47% of patients treated with an asparaginase comparator.
Estonian: Teises uuringus, milles osales 76 pärast varasemat ravi taastekkinud vähiga last, oli ravi järel ilma vähita patsiente Oncaspari uuringurühmas ligikaudu 40% (kellest osa oli allergiline muude asparaginaasravimite suhtes) ja asparaginaasi sisaldava võrdlusravimi rühmas 47%.
English: The active substance (pegaspargase) contains the enzyme asparaginase which works by breaking up and reducing the blood levels of the amino acid asparagine.
Estonian: Toimeaine (pegaspargaas) sisaldab ensüümi asparaginaasi, mis lõhustab aminohapet asparagiini ja vähendab selle sisaldust veres.
English: How does Oncaspar work?
Estonian: Kuidas Oncaspar toimib?
English: In a study in 118 children newly diagnosed with ALL, 75% of those treated with Oncaspar (in combination with other medicines) were free of the cancer after 7 years, without having relapse or a new cancer during that period.
Estonian: Uuringus, milles osales 118 ägeda lümfoblastleukeemia esmadiagnoosiga last, oli patsiente, kellel ei esinenud vähki 7 aastat pärast ravi ega tekkinud relapsi või uut vähki, Oncaspariga (kombinatsioonis teiste ravimitega) ravitutest 75% ja muu asparaginaasiga ravitutest 66%.
English: For the full list of side effects of Oncaspar, see the package leaflet.
Estonian: Oncaspari kõrvalnähtude täielik loetelu on pakendi infolehel.
English: How is Oncaspar used?
Estonian: Kuidas Oncasparit kasutatakse?
English: Oncaspar must not be used in patients with severe liver disease, patients who have ever had pancreatitis (including pancreatitis caused by previous asparaginase treatments) or patients who have had severe bleeding or serious blood clots following asparaginase treatment.
Estonian: Oncasparit ei tohi kasutada raske maksahaigusega patsiendid ega patsiendid, kellel on esinenud pankreatiit või kellel on pärast asparaginaasravi tekkinud raske verejooks või raske tromboos.
English: Oncaspar can only be obtained with a prescription and only healthcare professionals with experience of cancer treatments should prescribe and give the medicine.
Estonian: Oncaspar on retseptiravim, mida tohivad määrata ja manustada üksnes vähiravis kogenud tervishoiutöötajad.
English: What benefits of Oncaspar have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Oncaspari kasulikkus?
English: It contains the active substance pegaspargase.
Estonian: Oncaspar sisaldab toimeainena pegaspargaasi.
English: Oncaspar is normally given every 14 days by injection into a muscle or by infusion (drip) into a vein, with the dose depending on age and body surface area.
Estonian: Oncasparit manustatakse tavaliselt iga 14 päeva järel intramuskulaarse süstena või veeniinfusioonina.
English: An overview of Oncaspar and why it is authorised in the EU
Estonian: Ülevaade ravimist Oncaspar ja ELis müügiloa väljastamise põhjendus
English: Oncaspar is a cancer medicine used in adults and children to treat acute lymphoblastic leukaemia (ALL), a cancer of white blood cells called lymphoblasts.
Estonian: Oncaspar on vähiravim, mis on näidustatud ägeda lümfoblastleukeemia (ALL) raviks täiskasvanutel ja lastel.
English: Orfadin nitisinone
Estonian: Orfadin nitisinoon
English: What measures are being taken to ensure the safe and effective use of Orfadin?
Estonian: Mis meetmed võetakse, et tagada Orfadini ohutu ja efektiivne kasutamine?
English: Orfadin is intended for long-term use.
Estonian: Orfadin on ette nähtud pikaajaliseks kasutamiseks.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Orfadin on 21 February 2005.
Estonian: Euroopa Komisjon andis Orfadini müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 21. veebruaril 2005.
English: A risk management plan has been developed to ensure that Orfadin is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Orfadini võimalikult ohutu kasutamine.
English: It is available as capsules (2 mg, 5 mg, 10 mg and 20 mg) and as a suspension (4 mg/ml) to be taken by mouth.
Estonian: Seda turustatakse kapslitena (2 mg, 5 mg, 10 mg ja 20 mg) ja suukaudse suspensioonina (4 mg/ml).
English: The largest study of Orfadin was carried out in 257 patients in 87 different hospitals in 25 countries, as part of a ‘compassionate-use' programme.
Estonian: Orfadini suurim uuring, milles osales 25 riigi 87 haigla 257 patsienti, toimus eriloaga kasutamise programmi alusel.
English: This is a programme through which doctors can request a medicine for one of their patients before the medicine is fully authorised.
Estonian: See on programm, mille kaudu arstid võivad taotleda ravimi kasutamist mõnel patsiendil teatud haiguse ravimiseks enne ravimi täieliku müügiloa andmist.
English: Thrombocytopenia (low blood platelet counts), leucopenia (low white blood cell counts), granulocytopenia (low levels of granulocytes, a type of white blood cell), conjunctivitis (inflammation of the membrane that lines the eyelid), corneal opacity (clouding of the cornea, the transparent layer in front of the pupil), keratitis (inflammation of the cornea), photophobia (increased sensitivity of the eyes to light) and eye pain are also common (seen in between 1 and 10 patients in 100).
Estonian: Trombotsütopeenia (vereliistakute vähesus), leukopeenia (vere valgeliblede vähesus), granulotsütopeenia (vere teatud valgeliblede granulotsüütide vähesus), konjunktiviit (silma sidekesta põletik), silma sarvkesta hägusus, keratiit (sarvkestapõletik), fotofoobia (valguskartus) ja silmavalu on samuti sagedad (esinenud 1-10 patsiendil 100st).
English: This is a summary of the European public assessment report (EPAR) for Orfadin.
Estonian: See on ravimi Orfadin Euroopa avaliku hindamisaruande kokkuvõte.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Orfadin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Orfadini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
English: This is a rare disease in which the body is unable to completely break down the amino acid tyrosine, and harmful substances are formed, causing serious liver problems and liver cancer.
Estonian: See on haruldane haigus, mille korral organism ei suuda täielikult lagundada aminohapet türosiini, mille tulemusena tekivad kahjulikud ained, mis põhjustavad raskeid maksaprobleeme ja maksavähki.
English: Therefore, the CHMP decided that Orfadin's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Seetõttu otsustas inimravimite komitee, et Orfadini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The CHMP noted that Orfadin seems to be an effective treatment for HT-1, particularly if it is started early, before the patient's liver is too damaged.
Estonian: Inimravimite komitee märkis, et Orfadin näib olevat HT-1 ravis efektiivne, eelkõige kui selle kasutamist alustatakse vara, enne patsiendi maksa liigset kahjustumist.
English: As the company had submitted the additional information requested, the ‘exceptional circumstances' ended on 21 September 2009.
Estonian: Et ettevõte esitas soovitud lisateabe, tühistati 21. septembril 2009 müügiloa erandkorras väljastatus.
English: Treatment should be started as early as possible and the dose of Orfadin adjusted according to the patient's response and body weight.
Estonian: Ravi tuleb alustada nii vara kui võimalik ning Orfadini annus tuleb kohandada patsiendi ravivastuse ja kehakaalu järgi.
English: Treatment with Orfadin leads to high levels of tyrosine in the blood (due to the medicine's mode of action); this side effect is seen in more than 1 patient in 10.
Estonian: Orfadiniga toimuva ravi tagajärjel suureneb türosiinisisaldus veres (ravimi toimemehhanismi tõttu); see kõrvalnäht esineb enam kui 1 patsiendil 10st.
English: Orfadin was originally authorised under ‘exceptional circumstances', because, as the disease is rare, limited information was available at the time of the approval.
Estonian: Esialgu kiideti Orfadin heaks erandkorras, sest haigus esineb harva ja ravimi heakskiitmise ajal ei olnud piisavalt teavet.
English: The recommended starting dose is 1 mg per kilogram body weight per day, divided into two doses.
Estonian: Soovitatav lähteannus on 1 mg kehakaalu kg kohta ööpäevas, jagatuna kaheks annuseks.
English: Orfadin is used to treat hereditary tyrosinaemia type 1 (HT-1).
Estonian: Orfadini kasutatakse päriliku I tüüpi türosineemia (HT-1) raviks.
English: Why has Orfadin been approved?
Estonian: Miks Orfadin heaks kiideti?
English: Because the number of patients with HT-1 is low, the disease is considered ‘rare', and Orfadin was designated an ‘orphan medicine' (a medicine used in rare diseases) on 29 December 2000.
Estonian: Et HT-1-ga patsientide arv on väike ja see haigus esineb harva, nimetati Orfadin 29. detsembril 2000 harvikravimiks.
English: What is Orfadin?
Estonian: Mis on Orfadin?
English: The main benefit of Orfadin is to greatly extend life expectancy.
Estonian: Orfadini peamine kasulikkus on oluliselt suurenenud elulemus.
English: Other information about Orfadin
Estonian: Muu teave Orfadini kohta
English: For the full list of all side effects and restrictions with Orfadin, see the package leaflet.
Estonian: Orfadini kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: These amino acids are normally found in proteins in foods and drinks.
Estonian: Need aminohapped on tavalistes toiduvalkudes.
English: Orfadin is a medicine that contains the active substance nitisinone.
Estonian: Orfadin on ravim, mis sisaldab toimeainena nitisinooni.
English: For example, a baby less than two months old with HT-1 would normally have only a 28% chance of surviving for five years using a modified diet alone.
Estonian: Näiteks üksnes eridieeti kasutades on HT-1-ga alla 2-kuusel imikul tõenäosus elada 5-aastaseks ainult 28%.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Orfadin, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Orfadini omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: What is the risk associated with Orfadin?
Estonian: Mis riskid Orfadiniga kaasnevad?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Orfadin.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Patients with HT-1 lack one of these enzymes, so tyrosine is not properly eliminated but is transformed into harmful substances.
Estonian: HT-1-ga patsientidel puudub neist üks ensüüm, mille tõttu jääb türosiin organismi ja see muutub kahjulikeks aineteks.
English: Many of these side effects can be the result of high tyrosine levels caused by patients not eating the right foods.
Estonian: Neist kõrvalnähtudest mitut põhjustab suur türosiinisisaldus, mis tuleneb valest toitumisest.
English: However, as tyrosine remains in the body during Orfadin treatment, patients need to eat a special diet low in tyrosine.
Estonian: Et türosiin püsib Orfadini-ravi ajal organismis, vajavad patsiendid siiski eridieeti, mis sisaldab türosiini vähe.
English: How does Orfadin work?
Estonian: Kuidas Orfadin toimib?
English: The active substance in Orfadin, nitisinone, blocks an enzyme that converts tyrosine into harmful substances.
Estonian: Orfadini toimeaine nitisinoon blokeerib türosiini kahjulikeks aineteks muutva ensüümi.
English: The oral suspension is for children who have difficulty swallowing capsules.
Estonian: Suukaudne lahus on ette nähtud lastele, kes ei suuda neelata kapsleid.
English: The study looked at the effect of Orfadin on survival, and compared this with reports published in medical journals describing survival in patients with HT-1 who were only receiving a modified diet.
Estonian: Uuringu tulemusi võrreldi meditsiini teadusajakirjades avaldatud andmetega nende HT-1-ga patsientide kohta, kes kasutasid ainult eridieeti.
English: What benefit has Orfadin shown during the studies?
Estonian: Milles seisneb uuringute põhjal Orfadini kasulikkus?
English: Orfadin also provides a better outcome for patients than that reported in the literature in patients eating a modified diet alone.
Estonian: Orfadin mõjub patsiendile ka paremini kui üksnes eridieet, mille kohta on andmed teaduskirjandusest.
English: Treatment with Orfadin should be started and monitored by doctors who have experience in the treatment of patients with HT-1.
Estonian: Ravi Orfadiniga tohib alustada üksnes HT-1-ga patsientide ravis kogenud arst ning ravi peab toimuma tema järelevalve all.
English: The sooner treatment is started, the better the chances of survival.
Estonian: Orfadini lisamisel raviskeemile suureneb elulemuse tõenäosus 82%-ni. Mida varem ravi alustatakse, seda suurem on elulemus.
English: Orfadin is used together with a diet that restricts the intake of the amino acids tyrosine and phenylalanine.
Estonian: Orfadini kasutatakse koos aminohappeid türosiini ja fenüülalaniini vähe sisaldava dieediga.
English: How has Orfadin been studied?
Estonian: Kuidas Orfadini uuriti?
English: The full EPAR for Orfadin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Orfadini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Kui vajate Orfadiniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: How is Orfadin used?
Estonian: Kuidas Orfadini kasutatakse?
English: What is Orfadin used for?
Estonian: Milleks Orfadini kasutatakse?
English: The medicine can only be obtained with a prescription.
Estonian: Orfadin on retseptiravim.
English: ATC vet code: QD11AH90.
Estonian: ATC vet kood: QD11AH90.
English: Via del Commercio 25/27 63100 Marino Del Tronto (AP) ITALY
Estonian: Via del Commercio 25/27 63100 Marino Del Tronto (AP) ITAALIA
English: Neither of these clinical pathology changes appeared clinically significant.
Estonian: Ükski patoloogiline muutus ei tundunud kliiniliselt oluline.
English: Do not use in dogs less than 12 months of age or less than 3 kg bodyweight.
Estonian: Mitte kasutada alla 12 kuu vanustel või alla 3 kg kaaluvatel koertel.
English: Date of last renewal: 26/07/2018.
Estonian: Esmase müügiloa väljastamise kuupäev: 12.09.2013 Müügiloa viimase uuendamise kuupäev: 26.07.2018
English: 20 tablets 50 tablets 100 tablets
Estonian: 20 tabletti 50 tabletti 100 tabletti
English: Following intravenous and oral administration, the terminal t1/2s were similar at 3.5 and 4.1 hours respectively.
Estonian: Pärast veenisisest ja suukaudset manustamist olid lõplikud t1/2 sarnased: vastavalt 3,5 ja 4,1 tundi.
English: Oclacitinib is a Janus kinase (JAK) inhibitor.
Estonian: Oklatsitiniib on Janus-kinaasi (JAK) inhibiitor.
English: The absolute bioavailability of oclacitinib maleate was 89%.
Estonian: Oklatsitiniibmaleaadi täielik biosaadavus oli 89%.
English: These tablets can be administered with or without food.
Estonian: Neid tablette võib manustada koos toiduga või ilma.
English: The prandial state of the dog does not significantly affect the rate or extent of its absorption.
Estonian: Koera söögiajad ei mõjuta olulisel määral ravimi imendumise kiirust ega ulatust.
English: Lactose monohydrate Hypromellose (E464) Titanium dioxide (E171) Macrogol 400 (E1521)
Estonian: Tableti kate: laktoosmonohüdraat, hüpromelloos (E464), titaandioksiid (E171), makrogool 400 (E1521).
English: Regarding susceptibility to infection and neoplastic conditions, see section 4.5.
Estonian: Vastuvõtlikkuse kohta nakkushaigustele ja kasvajalistele seisunditele vt lõigus 4.5.
English: Therefore, the risk of metabolic drug-drug interactions due to oclacitinib inhibition is very low.
Estonian: Seetõttu on oklatsitiniibi pärssimise tõttu ravimite koostoime oht väga väike.
English: Do not use this veterinary medicinal product after the expiry date which is stated on the blister or bottle after EXP.
Estonian: Ärge kasutage veterinaarravimit pärast kõlblikkusaega, mis on märgitud mullpakendil või pudelil pärast EXP/ Kõlblik kuni.
English: 1BANNEX II
Estonian: 1BLISA II
English: Treatment-related clinical pathology changes were restricted to an increase in mean serum cholesterol and a decrease in mean leukocyte count, however, all mean values remained within the laboratory reference range.
Estonian: Raviga kaasnevad patoloogilised kliinilised muutused piirdusid seerumi keskmise kolesteroolisisalduse suurenemise ja leukotsüütide arvu vähenemisega, kuigi kõik näitajad jäid referentsväärtuste piiresse.
English: All tablets strengths are packaged in either aluminium/PVC/Aclar blisters (each strip containing 10 film-coated tablets) packed into an outer cardboard box, or white HDPE plastic bottle with child resistant closure.
Estonian: Kõik tablettide tugevused on pakitud kas alumiiniumist/PVCst/Alcarist mullpakendisse (iga riba sisaldab 10 polümeerikattega tabletti), mis on pakendatud välimisse pappkarpi või lapsekindla korgiga valgesse HDPE plastpudelisse.
English: Pack sizes of 20, 50 or 100 tablets.
Estonian: Pakendis on 20, 50 või 100 tabletti.
English: Dogs receiving Apoquel tablets should therefore be monitored for the development of infections and neoplasia.
Estonian: Seetõttu peab Apoqueli tablette tarvitavaid koeri regulaarselt jälgima nakkushaiguste ja kasvajate suhtes.
English: The requirement for long-term maintenance therapy should be based on an individual benefit-risk assessment.
Estonian: Pikaajalise säilitusravi vajadus peab põhinema individuaalsel kasulikkuse ja riski hinnangul.
English: One major oxidative metabolite was identified in plasma and urine.
Estonian: Plasmas ja uriinis on kindlaks tehtud üks peamine oksüdatiivne metaboliit.
English: Oclacitinib modulates the immune system and may increase susceptibility to infection and exacerbate neoplastic conditions.
Estonian: Oklatsitiniib toimib immuunsüsteemile ja võib suurendada vastuvõtlikkust nakkushaigustele ning kiirendada kasvajaliste seisundite edasiarenemist.
English: Any remaining half tablet should be placed back in the opened blister and stored in the original cardboard carton, or in the HDPE bottle (for a maximum of 3 days).
Estonian: Kõik allesjäänud poolikud tabletid peab asetama tagasi kas avatud mullpakendisse ja säilitama (kõige rohkem 3 päeva) originaalpappkarbis või HDPE pudelisse (kõige rohkem 3 päevaks).
English: Papilloma was considered treatment related, but not dose related.
Estonian: Papilloome peeti raviga seonduvaks, kuid mitte annusest sõltuvaks.
English: It can inhibit the function of a variety of cytokines dependent on JAK enzyme activity.
Estonian: See võib pärssida mitmete JAK-ensüümist sõltuvate tsütokiinide funktsiooni.
English: Pharmacotherapeutic group: Agents for dermatitis, excluding corticosteroids.
Estonian: Farmakoterapeutiline rühm: dermatiidiravimid, v.a kortikosteroidid.
English: Shelf life of the veterinary medicinal product as packaged for sale in bottles: 18 months.
Estonian: Müügipakendis veterinaarravimi kõlblikkusaeg (pudelis): 18 kuud.
English: Oclacitinib is metabolised in the dog to multiple metabolites.
Estonian: Oklatsitiniib lagundatakse koera organismis mitmeteks metaboliitideks.
English: However, oclacitinib may also exert effects on other cytokines (for example, those involved in host defence or haematopoiesis) with the potential for unwanted effects.
Estonian: Samas võib oklatsitiniib mõjutada ka teisi tsütokiine (nt peremeesorganismi kaitsemehhanismides või hematopoeesis osalevad tsütokiinid), mis võib põhjustada kõrvaltoimeid.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Estonian: Kõrvaltoimete esinemissagedus on defineeritud järgnevalt: - väga sage (kõrvaltoime(d) ilmnes(id) rohkem kui 1-l loomal 10-st ravitud loomast) - sage (rohkem kui 1-l, kuid vähem kui 10-l loomal 100-st ravitud loomast) - aeg-ajalt (rohkem kui 1-l, kuid vähem kui 10-l loomal 1000-st ravitud loomast) - harv (rohkem kui 1-l, kuid vähem kui 10-l loomal 10 000-st ravitud loomast).
English: However, the findings of this study indicated a reduction in serological response to vaccination with CPI and RV in puppies being treated with oclacitinib compared to untreated controls.
Estonian: Samas viitasid antud uuringu tulemused, et oklatsitiniibi saanud kutsikatel oli pärast CPI ja RV vastu vaktsineerimist seroloogiline vastus tagasihoidlikum võrreldes ravi mittesaanud kontrollidega.
English: The impact of oclacitinib administration on vaccination with modified live vaccines, canine parvovirus (CPV), canine distemper virus (CDV) and canine parainfluenza (CPI) and inactivated rabies vaccine (RV), on 16 week old vaccine naïve puppies has been studied.
Estonian: Oklatsitiniibi mõju vaktsineerimisele modifitseeritud elusvaktsiinide, koerte parvoviiruse (CPV), koerte katkuviiruse (CDV) ja koerte paragripi (CPI) ning inaktiveeritud marutaudi vaktsiiniga (RV) uuriti 16 nädala vanustel vaktsineerimata kutsikatel.
English: Any remaining half tablets should be discarded after 3 days.
Estonian: Kõik allesjäänud poolikud tabletid peab 3 päeva möödudes ära viskama.
English: Anaemia and lymphoma have been reported very rarely in spontaneous reports.
Estonian: Spontaansetes teadetes on väga harva teatatud aneemiast ja lümfoomist.